Современные представления о консервативной терапии доброкачественной гиперплазии предстательной железы Как можно предотвратить прогрессирование заболевания?
Современные представления о консервативной терапии доброкачественной гиперплазии предстательной железы Как можно предотвратить прогрессирование заболевания?
Аляев Ю.Г., Винаров А.З., Локшин К.Л., Спивак Л.Г. Современные представления о консервативной терапии доброкачественной гиперплазии предстательной железы Как можно предотвратить прогрессирование заболевания? Consilium Medicum. 2008; 10 (2): 22–24.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997;158:481–7
2. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J Urol 1999;162:1301–06.
3. Roehrborn C, Fuh V, Ruane P et al. The relationship between total and free PSA, prostate volume and age in men age 40–60 with no clinical diagnosis of benign prostatic hyperplasia necessitating therapy. J Urol 2000;163(Suppl): 252A.
4. EAU Recommendations on Benign Prostatic Hyperplasia. Update March 2004.(Eds. J. de la Rosette et al). Internet: http://www.uroweb.org/fileadmin/user_upload/Guidelines/BPH.pdf
5. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003 Dec;44(6):650–5.
6. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387–98.
7. Wilt TJ, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(3):CD001423.
8. Boyle P, Robertson C, Lowe F et al. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533–9
9. Debruyne F, Koch G, Boyle P, et al. Groupe d'etude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Prog Urol 2002 Jun;12(3):384–94.
10. Debruyne F, Boyle P, Calais Da Silva F, et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol. 2004 Jun;45(6):773–9; discussion 779–80
11. Винаров А.З. Медикаментозное лечение больных гиперплазией предстательной железы. Дис... д-ра мед. наук. М., 1999.
12. Navarrete Vela R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003 Nov;44(5):549–55.
2. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Treatment for benign prostatic hyperplasia among community dwelling men: The Olmsted County study of urinary symptoms and health status. J Urol 1999;162:1301–06.
3. Roehrborn C, Fuh V, Ruane P et al. The relationship between total and free PSA, prostate volume and age in men age 40–60 with no clinical diagnosis of benign prostatic hyperplasia necessitating therapy. J Urol 2000;163(Suppl): 252A.
4. EAU Recommendations on Benign Prostatic Hyperplasia. Update March 2004.(Eds. J. de la Rosette et al). Internet: http://www.uroweb.org/fileadmin/user_upload/Guidelines/BPH.pdf
5. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003 Dec;44(6):650–5.
6. McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387–98.
7. Wilt TJ, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;(3):CD001423.
8. Boyle P, Robertson C, Lowe F et al. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533–9
9. Debruyne F, Koch G, Boyle P, et al. Groupe d'etude PERMAL. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Prog Urol 2002 Jun;12(3):384–94.
10. Debruyne F, Boyle P, Calais Da Silva F, et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol. 2004 Jun;45(6):773–9; discussion 779–80
11. Винаров А.З. Медикаментозное лечение больных гиперплазией предстательной железы. Дис... д-ра мед. наук. М., 1999.
12. Navarrete Vela R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003 Nov;44(5):549–55.
Авторы
Ю.Г. Аляев, А.З. Винаров, К.Л. Локшин, Л.Г Спивак
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.